Q2 EPS Estimates for Vor Biopharma Reduced by HC Wainwright

Vor Biopharma Inc. (NYSE:VOR - Free Report) - Analysts at HC Wainwright reduced their Q2 2025 earnings estimates for shares of Vor Biopharma in a note issued to investors on Monday, June 30th. HC Wainwright analyst S. Ramakanth now expects that the company will earn ($1.25) per share for the quarter, down from their previous estimate of ($0.18). HC Wainwright has a "Buy" rating and a $3.00 price objective on the stock. The consensus estimate for Vor Biopharma's current full-year earnings is ($1.42) per share. HC Wainwright also issued estimates for Vor Biopharma's Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.18) EPS, FY2025 earnings at ($0.88) EPS, Q1 2026 earnings at ($0.18) EPS, Q2 2026 earnings at ($0.18) EPS, Q3 2026 earnings at ($0.18) EPS, Q4 2026 earnings at ($0.16) EPS, FY2026 earnings at ($0.69) EPS, FY2027 earnings at ($0.65) EPS, FY2028 earnings at $0.05 EPS and FY2029 earnings at $0.24 EPS.

VOR has been the topic of a number of other research reports. Wedbush reiterated an "outperform" rating on shares of Vor Biopharma in a research note on Thursday, June 26th. JMP Securities restated a "market perform" rating and issued a $6.00 price target on shares of Vor Biopharma in a research report on Friday, May 9th. Oppenheimer restated an "outperform" rating and issued a $8.00 price target on shares of Vor Biopharma in a research report on Friday, March 21st. Baird R W lowered shares of Vor Biopharma from a "strong-buy" rating to a "hold" rating in a research report on Thursday, May 8th. Finally, Citizens Jmp lowered shares of Vor Biopharma from a "strong-buy" rating to a "hold" rating in a research report on Friday, May 9th. Four analysts have rated the stock with a hold rating and six have given a buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $5.63.

Vor Biopharma Price Performance

Shares of NYSE VOR traded up $0.44 during mid-day trading on Wednesday, reaching $1.89. 24,491,873 shares of the company traded hands, compared to its average volume of 4,248,899. Vor Biopharma has a fifty-two week low of $0.13 and a fifty-two week high of $2.04. The firm has a market cap of $235.55 million, a PE ratio of -1.14 and a beta of 2.04. The stock has a fifty day simple moving average of $0.45 and a 200-day simple moving average of $0.85.

Hedge Funds Weigh In On Vor Biopharma

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. GABELLI & Co INVESTMENT ADVISERS INC. purchased a new position in Vor Biopharma during the 4th quarter worth approximately $33,000. Money Concepts Capital Corp grew its position in Vor Biopharma by 106.1% during the 1st quarter. Money Concepts Capital Corp now owns 51,535 shares of the company's stock worth $37,000 after purchasing an additional 26,535 shares in the last quarter. Virtu Financial LLC purchased a new position in Vor Biopharma during the 4th quarter worth approximately $60,000. XTX Topco Ltd acquired a new stake in shares of Vor Biopharma during the 4th quarter valued at $80,000. Finally, Goldman Sachs Group Inc. boosted its stake in shares of Vor Biopharma by 218.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company's stock valued at $61,000 after buying an additional 58,247 shares during the period. 97.29% of the stock is currently owned by hedge funds and other institutional investors.

About Vor Biopharma

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.